EP1263453A4 - Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix - Google Patents
Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrixInfo
- Publication number
- EP1263453A4 EP1263453A4 EP01939971A EP01939971A EP1263453A4 EP 1263453 A4 EP1263453 A4 EP 1263453A4 EP 01939971 A EP01939971 A EP 01939971A EP 01939971 A EP01939971 A EP 01939971A EP 1263453 A4 EP1263453 A4 EP 1263453A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- regulating
- biologically active
- active compounds
- polymer matrix
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17413799P | 1999-12-31 | 1999-12-31 | |
US174137P | 1999-12-31 | ||
PCT/US2001/000030 WO2001049249A2 (en) | 1999-12-31 | 2001-01-02 | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1263453A2 EP1263453A2 (en) | 2002-12-11 |
EP1263453A4 true EP1263453A4 (en) | 2008-02-20 |
Family
ID=22634986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01939971A Ceased EP1263453A4 (en) | 1999-12-31 | 2001-01-02 | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1263453A4 (en) |
JP (1) | JP2003519164A (en) |
AU (1) | AU784226B2 (en) |
CA (1) | CA2396037A1 (en) |
WO (1) | WO2001049249A2 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU775905B2 (en) * | 1999-12-31 | 2004-08-19 | Rutgers, The State University | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
ATE551339T1 (en) | 2003-11-05 | 2012-04-15 | Sarcode Bioscience Inc | MODULATORS OF CELLULAR ADHESION |
CN102617557A (en) | 2005-05-17 | 2012-08-01 | 萨可德生物科学公司 | Compositions and methods for treatment of eye disorders |
US8315700B2 (en) | 2006-02-08 | 2012-11-20 | Tyrx, Inc. | Preventing biofilm formation on implantable medical devices |
US8636753B2 (en) | 2006-02-08 | 2014-01-28 | Tyrx, Inc. | Temporarily stiffened mesh prostheses |
US9265865B2 (en) | 2006-06-30 | 2016-02-23 | Boston Scientific Scimed, Inc. | Stent having time-release indicator |
MX2009004821A (en) | 2006-11-06 | 2009-11-23 | Tyrx Pharma Inc | Mesh pouches for implantable medical devices. |
US9023114B2 (en) | 2006-11-06 | 2015-05-05 | Tyrx, Inc. | Resorbable pouches for implantable medical devices |
EP2129339B1 (en) | 2007-03-29 | 2015-03-04 | Tyrx, Inc. | Biodegradable, polymer coverings for breast implants |
MX2009011785A (en) | 2007-05-02 | 2010-03-04 | Tyrx Pharma Inc | Dihydroxybenzoate polymers and uses thereof. |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2008317473B2 (en) | 2007-10-19 | 2014-07-17 | Bausch + Lomb Ireland Limited | Compositions and methods for treatment of diabetic retinopathy |
WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8652525B2 (en) | 2008-07-10 | 2014-02-18 | Tyrx, Inc. | NSAID delivery from polyarylates |
ES2624828T3 (en) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others |
EP2346537B1 (en) | 2008-09-22 | 2016-11-09 | Tyrx, Inc. | Linear polyesteramides from aminophenolic esters |
JP5847706B2 (en) * | 2009-06-01 | 2016-01-27 | タイレックス・インコーポレイテッドTyrx Inc. | Compositions and methods for preventing sternum wound infections |
US9839628B2 (en) | 2009-06-01 | 2017-12-12 | Tyrx, Inc. | Compositions and methods for preventing sternal wound infections |
US9080015B2 (en) * | 2009-07-31 | 2015-07-14 | Rutgers, The State University Of New Jersey | Biocompatible polymers for medical devices |
US8409279B2 (en) | 2009-10-01 | 2013-04-02 | Lipose Corporation | Breast implant implantation method and apparatus |
WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
US9155735B2 (en) | 2010-08-25 | 2015-10-13 | Tyrx, Inc. | Medical device coatings |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP2637713B1 (en) | 2010-11-12 | 2016-04-20 | Tyrx, Inc. | Anchorage devices comprising an active pharmaceutical ingredient |
AU2012283875B2 (en) | 2011-07-20 | 2016-05-12 | Medtronic, Inc. | Drug eluting mesh to prevent infection of indwelling transdermal devices |
WO2014018748A1 (en) | 2012-07-25 | 2014-01-30 | Sarcode Bioscience Inc. | Lfa-1 inhibitor and polymorph thereof |
EP3718557A3 (en) | 2013-02-25 | 2020-10-21 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing |
WO2014137454A1 (en) | 2013-03-07 | 2014-09-12 | Tyrx, Inc. | Methods and compositions to inhibit the assemblage of microbial cells irreversibly associated with surfaces of medical devices |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
MY176976A (en) | 2013-10-10 | 2020-08-28 | Bausch Health Ireland Ltd | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
CN105431178A (en) | 2013-11-08 | 2016-03-23 | 泰尔克斯公司 | Antimicrobial compositions and methods for preventing infection in surgical incision sites |
WO2016020308A1 (en) * | 2014-08-04 | 2016-02-11 | Janssen Sciences Ireland Uc | Compacted solid dosage form |
US10653744B2 (en) | 2016-01-11 | 2020-05-19 | Bausch Health Ireland Limited | Formulations and methods for treating ulcerative colitis |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587507A (en) * | 1995-03-31 | 1996-12-24 | Rutgers, The State University | Synthesis of tyrosine derived diphenol monomers |
WO1997019996A1 (en) * | 1995-11-27 | 1997-06-05 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
WO1998036013A1 (en) * | 1997-02-18 | 1998-08-20 | Rutgers, The State University | Monomers derived from hydroxy acids and polymers prepared therefrom |
WO1999024107A1 (en) * | 1997-11-07 | 1999-05-20 | Rutgers, The State University | Biodegradable, anionic polymers derived from the amino acid l-tyrosine |
WO1999029758A1 (en) * | 1997-12-12 | 1999-06-17 | Samyang Corporation | Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake |
WO1999052962A1 (en) * | 1998-04-13 | 1999-10-21 | Rutgers, The State University | The construction of copolymer libraries |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19719817A1 (en) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids |
EP1157421A1 (en) * | 1999-02-05 | 2001-11-28 | Alien Technology Corporation | Apparatuses and methods for forming assemblies |
-
2001
- 2001-01-02 JP JP2001549618A patent/JP2003519164A/en active Pending
- 2001-01-02 WO PCT/US2001/000030 patent/WO2001049249A2/en active Application Filing
- 2001-01-02 AU AU29255/01A patent/AU784226B2/en not_active Expired
- 2001-01-02 EP EP01939971A patent/EP1263453A4/en not_active Ceased
- 2001-01-02 CA CA002396037A patent/CA2396037A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587507A (en) * | 1995-03-31 | 1996-12-24 | Rutgers, The State University | Synthesis of tyrosine derived diphenol monomers |
WO1997019996A1 (en) * | 1995-11-27 | 1997-06-05 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
WO1998036013A1 (en) * | 1997-02-18 | 1998-08-20 | Rutgers, The State University | Monomers derived from hydroxy acids and polymers prepared therefrom |
WO1999024107A1 (en) * | 1997-11-07 | 1999-05-20 | Rutgers, The State University | Biodegradable, anionic polymers derived from the amino acid l-tyrosine |
WO1999029758A1 (en) * | 1997-12-12 | 1999-06-17 | Samyang Corporation | Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake |
WO1999052962A1 (en) * | 1998-04-13 | 1999-10-21 | Rutgers, The State University | The construction of copolymer libraries |
Non-Patent Citations (1)
Title |
---|
CHA Y ET AL: "a one-week subdermal delivery system for l-methadone based on biodegradable microcapsules", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 1, April 1988 (1988-04-01), pages 69 - 78, XP002143620, ISSN: 0168-3659 * |
Also Published As
Publication number | Publication date |
---|---|
AU2925501A (en) | 2001-07-16 |
JP2003519164A (en) | 2003-06-17 |
WO2001049249A2 (en) | 2001-07-12 |
WO2001049249A3 (en) | 2002-01-17 |
EP1263453A2 (en) | 2002-12-11 |
CA2396037A1 (en) | 2001-07-12 |
AU784226B2 (en) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1263453A4 (en) | Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix | |
AU5914999A (en) | Controlled release drug delivery | |
HUP0301242A3 (en) | Controlled release drug dosage form | |
IL132453A0 (en) | Gastroretentive controlled release microspheres for improve drug delivery | |
AU2180400A (en) | A pharmaceutical combination for the treatment of depression | |
IL121275A (en) | Controlled release formulation for poorly soluble basic drugs | |
AU5335698A (en) | Pharmaceutical formulations with delayed drug release | |
AU7839900A (en) | Reusable medication delivery device | |
EP1251864A4 (en) | Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release | |
IL145581A0 (en) | A modified release pharmaceutical composition comprising amoxycillin | |
AU5609998A (en) | Tablet for the controlled release of active agents | |
AU4464897A (en) | Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a matrix | |
AU4328800A (en) | Pharmaceutical formulation | |
AU2003240654A1 (en) | Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release | |
ZA988718B (en) | Drug formulation having controlled release of active compound | |
IL134075A0 (en) | Analgesic with controlled active substance release | |
AU5812800A (en) | Pharmaceutical preparation | |
AU2773597A (en) | Pharmaceutical compositions for the sustained release of insoluble active principles | |
AU1650401A (en) | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | |
AU5026599A (en) | A wet granulation method for preparing a stable pharmaceutical formulation | |
AU1650501A (en) | 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient | |
IL148543A0 (en) | Pharmaceutical carrier formulation | |
AU7887400A (en) | A slow release pharmaceutical composition | |
AU3839900A (en) | Pharmaceutical formulation | |
AU6866700A (en) | Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020723 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
R17P | Request for examination filed (corrected) |
Effective date: 20020723 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080121 |
|
17Q | First examination report despatched |
Effective date: 20080718 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20110207 |